Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Consensus Recommendation of “Hold” from Brokerages

Posted by Defense World Staff on May 5th, 2023

Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) has received a consensus recommendation of “Hold” from the nine research firms that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $19.25.

A number of research analysts have recently weighed in on the company. Mizuho restated a “buy” rating and issued a $31.00 price target on shares of Atara Biotherapeutics in a research report on Tuesday, February 7th. EF Hutton Acquisition Co. I reissued a “buy” rating and set a $25.00 price objective on shares of Atara Biotherapeutics in a research report on Thursday, February 9th. HC Wainwright decreased their target price on Atara Biotherapeutics from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, February 9th. Finally, StockNews.com initiated coverage on shares of Atara Biotherapeutics in a research report on Thursday, March 16th. They set a “hold” rating for the company.

Atara Biotherapeutics Stock Performance

Shares of NASDAQ ATRA opened at $2.75 on Friday. Atara Biotherapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $9.34. The firm’s 50-day simple moving average is $3.01 and its 200 day simple moving average is $3.81. The stock has a market cap of $265.73 million, a price-to-earnings ratio of -1.23 and a beta of 0.96.

Atara Biotherapeutics (NASDAQ:ATRA – Get Rating) last announced its quarterly earnings data on Wednesday, February 8th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.11). The company had revenue of $0.22 million for the quarter, compared to the consensus estimate of $60.00 million. Atara Biotherapeutics had a negative net margin of 359.12% and a negative return on equity of 140.05%. On average, sell-side analysts predict that Atara Biotherapeutics will post -2.17 EPS for the current year.

Insider Activity

In other Atara Biotherapeutics news, CEO Pascal Touchon sold 15,679 shares of the stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $3.63, for a total transaction of $56,914.77. Following the transaction, the chief executive officer now directly owns 750,728 shares in the company, valued at approximately $2,725,142.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 34,330 shares of company stock valued at $129,165 in the last three months. 4.50% of the stock is currently owned by company insiders.

Institutional Trading of Atara Biotherapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC raised its position in shares of Atara Biotherapeutics by 893.8% during the third quarter. Nisa Investment Advisors LLC now owns 6,460 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 5,810 shares during the period. US Bancorp DE lifted its stake in Atara Biotherapeutics by 6,394.9% in the 3rd quarter. US Bancorp DE now owns 7,664 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 7,546 shares in the last quarter. First Republic Investment Management Inc. bought a new position in Atara Biotherapeutics during the 3rd quarter valued at about $38,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Atara Biotherapeutics by 27.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,469 shares of the biotechnology company’s stock worth $44,000 after buying an additional 2,909 shares during the period. Finally, Lazard Asset Management LLC purchased a new stake in Atara Biotherapeutics during the third quarter valued at approximately $45,000.

Atara Biotherapeutics Company Profile

(Get Rating)

Atara Biotherapeutics, Inc is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need.